Personalized Medicine, Availability, and Group Disparity: An Inquiry into How Physicians Perceive and Rate the Elements and Barriers of Personalized Medicine

被引:16
|
作者
Petersen, Katelin E. [1 ,2 ]
Prows, Cynthia A. [2 ,3 ]
Martin, Lisa J. [1 ,2 ]
Maglo, Koffi N. [4 ,5 ]
机构
[1] Univ Cincinnati, Sch Med, Dept Pediat, Cincinnati, OH 45221 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Patient Serv, Cincinnati, OH 45229 USA
[4] Univ Cincinnati, Dept Philosophy, Cincinnati, OH 45221 USA
[5] Univ Cincinnati, CCTST, Cincinnati, OH 45221 USA
关键词
Genetic testing; Health equality; Individualized healthcare; Perceptions; Personalized medicine; Pharmacogenomics; Race; GENOMIC MEDICINE; AFRICAN-AMERICAN; RESPONSE RATES; WARFARIN; RACE; PHARMACOGENETICS; DISEASE; HEALTH; CYP2C9; CARE;
D O I
10.1159/000362359
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: The success of personalized medicine depends on factors influencing the availability and implementation of its new tools to individualize clinical care. However, little is known about physicians' views of the availability of personalized medicine across racial/ethnic groups and the relationship between perceived availability and clinical implementation. This study examines physicians' perceptions of key elements/tools and potential barriers to personalized medicine in connection with their perceptions of the availability of the latter across subpopulations. Methods: Study subjects consisted of physicians recruited from Cincinnati Children's Hospital Medical Center and UC Health. An electronic survey conducted from September 2012 to November 2012 recruited 104 physicians. Wilcoxon rank sum analysis compared groups. Results: Physicians were divided about whether personalized medicine contributes to health equality, as 37.4% of them believe that personalized medicine is currently available only for some subpopulations. They also rated the importance of racial/ethnic background almost as high as the importance of genetic information in the delivery of personalized medicine. Actual elements of personalized medicine rated highest include family history, drug-drug interaction alerts in medical records, and biomarker measurements to guide therapy. Costs of gene-based therapies and genetic testing were rated the most significant barriers. The ratings of several elements and barriers were associated with perceived availability of personalized medicine across subpopulations. Conclusion: While physicians hold differing views about the availability and implementation of personalized medicine, they likewise establish complex relationships between race/ethnicity and personalized medicine that may carry serious implications for its clinical success. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:209 / 220
页数:12
相关论文
共 41 条
  • [31] The Terry Fox Research Institute's Ontario Dialogue: how will personalized medicine change health care?
    Curwin, K.
    Paige, C. J.
    Sutcliffe, S.
    CURRENT ONCOLOGY, 2011, 18 (01) : 33 - 38
  • [32] Personalized Medicine: how to Switch from the Concept to the Integration into the Clinical Development Plan to Obtain Marketing Authorization
    Becquemont, Laurent
    Bordet, Regis
    Cellier, Dominic
    THERAPIE, 2012, 67 (04): : 349 - 357
  • [33] Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients
    Ciardiello, Fortunato
    Adams, Richard
    Tabernero, Josep
    Seufferlein, Thomas
    Taieb, Julien
    Moiseyenko, Vladimir
    Ma, Brigette
    Lopez, Gustavo
    Vansteenkiste, Johan F.
    Esser, Regina
    Tejpar, Sabine
    ONCOLOGIST, 2016, 21 (03) : 292 - 300
  • [34] Knowledge, attitudes and practice regarding pharmacovigilance and adverse drug reaction reporting among physicians and pharmacists in Egypt: a step toward personalized medicine implementation
    Aziz, Alaa Abdel
    Rogers, Sara
    Hassanien, Omneya
    Shalaby, Lobna
    Nagy, Mohamed
    PERSONALIZED MEDICINE, 2022, 19 (06) : 495 - 507
  • [35] The use of omics profiling to improve outcomes of bone regeneration and osseointegration. How far are we from personalized medicine in dentistry?
    Calciolari, E.
    Donos, N.
    JOURNAL OF PROTEOMICS, 2018, 188 : 85 - 96
  • [36] An update of the Italian Stroke Organization-Stroke Prevention Awareness Diffusion Group guidelines on carotid endarterectomy and stenting: A personalized medicine approach
    Lanza, Gaetano
    Setacci, Carlo
    Ricci, Stefano
    Castelli, Patrizio
    Cremonesi, Alberto
    Lanza, Jessica
    Novali, Claudio
    Pratesi, Carlo
    Santalucia, Paola
    Speziale, Francesco
    Zaninelli, Augusto
    Gensini, Gian Franco
    INTERNATIONAL JOURNAL OF STROKE, 2017, 12 (05) : 560 - 567
  • [37] Pathology in the era of "Personalized Medicine": The need to learn how to integrate multivariate immunohistochemical and "omics" data with clinicopathologic information in a clinically relevant way"
    Marchevsky, Alberto M.
    Walts, Ann E.
    Wick, Mark R.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2019, 43
  • [38] Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework
    de Belvis, Antonio Giulio
    Pellegrino, Rossella
    Castagna, Carolina
    Morsella, Alisha
    Pastorino, Roberta
    Boccia, Stefania
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (07):
  • [39] Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning
    Krakow, Elizabeth F.
    Hemmer, Michael
    Wang, Tao
    Logan, Brent
    Arora, Mukta
    Spellman, Stephen
    Couriel, Daniel
    Alousi, Amin
    Pidala, Joseph
    Last, Michael
    Lachance, Silvy
    Moodie, Erica E. M.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2017, 186 (02) : 160 - 172
  • [40] Complexities of Personalized Medicine: How Genes, Drug-Drug Interactions, Dosing Schedules, and Other Factors Can Combine to Produce Clinically Meaningful Differences in a Drug's Effect
    Preskorn, Sheldon H.
    JOURNAL OF PSYCHIATRIC PRACTICE, 2013, 19 (05) : 397 - 405